Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open, comparative, multi-centre study which will recruit up to 66
patients. The objective is mainly to explore the safety and feasibility in neo-adjuvant
first-line ovarian cancer (including patients with primary peritoneal or fallopian tube
adenocarcinoma) of various combinations of durvalumab with chemotherapy with or without
tremelimumab.